{"id":"bisoprolol-pyridostgmine","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Increased salivation"}]},"_chembl":{"chemblId":"CHEMBL645","moleculeType":"Small molecule","molecularWeight":"325.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisoprolol is a selective beta-1 blocker that decreases cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Pyridostigmine is a cholinesterase inhibitor that prolongs acetylcholine action at the neuromuscular junction, improving muscle strength. This combination is used to address both cardiovascular and neuromuscular symptoms, particularly in conditions where both beta-blockade and cholinergic enhancement are therapeutically beneficial.","oneSentence":"Bisoprolol blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:21:07.486Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myasthenia gravis with concurrent hypertension or arrhythmia (investigational combination)"}]},"trialDetails":[{"nctId":"NCT02171988","phase":"PHASE4","title":"Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-03","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bisoprolol+pyridostgmine","genericName":"Bisoprolol+pyridostgmine","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bisoprolol blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission. Used for Myasthenia gravis with concurrent hypertension or arrhythmia (investigational combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}